Roche un­veils long-term da­ta from piv­otal spinal mus­cu­lar at­ro­phy tri­al

Bio­gen and No­var­tis have pre­vi­ous­ly rolled out long-term da­ta with their re­spec­tive spinal mus­cu­lar at­ro­phy ther­a­pies Spin­raza and Zol­gens­ma. Now, Roche is seek­ing to catch up with four-year da­ta for its block­buster ris­diplam, aka Evrys­di.

Pre­sent­ing at the Mus­cu­lar Dy­s­tro­phy As­so­ci­a­tion Clin­i­cal and Sci­en­tif­ic Con­fer­ence, the phar­ma gi­ant’s sub­sidiary Genen­tech un­veiled pos­i­tive da­ta Mon­day in pa­tients ages 2 to 25 from the SUN­FISH piv­otal study that had ei­ther type 2 or type 3 SMA. In short, Genen­tech said that its spinal mus­cu­lar at­ro­phy drug showed con­tin­ued ef­fi­ca­cy in pa­tients four years af­ter start­ing the ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER